Cerenome's subsidiary, CNSide Diagnostics, secured a national in-network agreement with Aetna for its CNSide® CSF Tumor Cell Enumeration test, effective November 1, 2026. This partnership expands patient access and establishes contracted reimbursement, which is a positive development for the company's revenue stream and market penetration.
Cerenome's subsidiary, CNSide Diagnostics, announced a national in-network agreement with Aetna for its CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration test. This is significant because it establishes contracted reimbursement rates and expands access to the diagnostic test for Aetna-insured patients, which can lead to increased utilization and revenue for Cerenome. The agreement, effective November 1, 2026, provides a clear path for broader adoption of their specialized diagnostic. For traders, this represents a long-term positive catalyst for Cerenome, as it solidifies a key revenue stream and market presence, reducing reimbursement uncertainty. The primary opportunity lies in the potential for increased sales volume and improved financial performance for Cerenome.